Instrumented Gait and Balance Analyses in Progressive Supranuclear Palsy and Mild Cognitive Impairment compared with Parkinson Disease

Objective: To explore instrumented gait and balance parameters in progressive supranuclear palsy (PSP) and amnestic mild cognitive impairment (aMCI) subjects compared to Parkinson disease (PD) and normal control (NC) cohorts. Background: Gait and balance impairment present variously in neurodegenerative diseases and provide valuable diagnostic clues, but cannot be easily detected through qualitative measures alone, particularly early in the course. Instrumented gait and balance analyses provide quantifiable metrics that can potentially differentiate between neurodegenerative diseases. There is a paucity of literature on comprehensive instrumented gait and balance measurements in PSP and aMCI, while PD has been studied more extensively. We studied objective gait and balance parameters in a cross-section of PSP and aMCI subjects. Design/Methods: 18 PSP and 19 aMCI subjects performed the instrumented Timed-Up-and-Go (iTUG) and instrumented Sway (iSWAY) tests using the APDM Mobility Lab, which utilizes six inertial sensors attached to the limbs and torso to quantify gait, turning and sway. Measurements were compared to 180 PD and 41 NC subjects enrolled in the NINDS Parkinson Disease Biomarkers Program study. ANOVA was performed to analyze between-group differences, followed by t-tests with Bonferroni correction for multiple comparisons using significance of p Results: 11 iTUG gait and turning parameters were significantly different in PSP versus other groups, while six iSWAY parameters were significantly different between PSP and NC, but for no other comparisons. In the aMCI cohort, four iTUG gait and turning variables were significantly different from the NC and three iTUG gait variables from the PD cohorts respectively, while iSWAY parameters were showed no significant difference. Conclusions: Instrumented gait and balance parameters show promise in augmenting diagnostic accuracy in PSP and aMCI. We intend to perform larger longitudinal studies with neuropathological correlation to verify the durability and discriminating power of these variables over time. Disclosure: Dr. Nguyen has research support from Eli Lilly u0026 Company. Dr. Brown has nothing to disclose. Dr. Logan has nothing to disclose. Dr. O9Suilleabhain has nothing to disclose. Dr. Dewey has received research support from NIH, Schwarz Pharma, and Elan. Dr. Quiceno has received personal compensation for activities with Accera as an advisory board member and speaker. Dr. Khemani has received personal compensation for activities with Lundbeck and Allergan as a member of the advisory board. Dr. Khemani has received research support from NINDS.